{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:21:59Z","timestamp":1767676919866},"reference-count":252,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1007\/s10689-004-9554-y","type":"journal-article","created":{"date-parts":[[2004,10,29]],"date-time":"2004-10-29T21:06:34Z","timestamp":1099083994000},"page":"265-281","source":"Crossref","is-referenced-by-count":32,"title":["Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations"],"prefix":"10.1007","volume":"3","author":[{"given":"Murray Joseph","family":"Casey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chhanda","family":"Bewtra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00000478-198104000-00004","volume":"5","author":"A Foyle","year":"1981","unstructured":"Foyle A, Al-Jabi M, McCaughey WT. Papillary peritoneal tumors in women. Am J Surg Pathol 1981;5:241?9.","journal-title":"Am J Surg Pathol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004347-198501000-00002","volume":"4","author":"CZ August","year":"1985","unstructured":"August CZ, Murad TM, Newton M. Multiple focal extraovarian serous carcinoma. Int J Gynecol Pathol 1985;4:11?23.","journal-title":"Int J Gynecol Pathol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0046-8177(89)90006-3","volume":"20","author":"U Raju","year":"1989","unstructured":"Raju U, Fine G, Greenawald KA et al. Primary papillary serous neoplasia of the peritoneum:a clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989;20:426?36.","journal-title":"Hum Pathol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5","volume":"64","author":"JC Dalrymple","year":"1989","unstructured":"Dalrymple JC, Bannatyne P, Russell P et al. Extraovarian peritoneal serous papillary carcinoma:a clinicopathologic study of 31 cases. Cancer 1989;64:110?5.","journal-title":"Cancer"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/1097-0142(19900915)66:6<1091::AID-CNCR2820660602>3.0.CO;2-F","volume":"66","author":"DT Ransom","year":"1990","unstructured":"Ransom DT, Patel SR, Keeney GL et al. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 1990;66:1091?4.","journal-title":"Cancer"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/gyno.1993.1267","volume":"51","author":"MA Killackey","year":"1993","unstructured":"Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface:matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993;51:171?4.","journal-title":"Gynecol Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1525-1438.1994.04010043.x","volume":"4","author":"JM Fowler","year":"1994","unstructured":"Fowler JM, Nieberg RK, Schooler TA et al. Peritoneal adeno-carcinoma (serous)of Mullerian type:a subgroup of women presenting with peritoneal carcinomatosis.Int J Gynecol Cancer 1994;4:43?51.","journal-title":"Int J Gynecol Cancer"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/gyno.1996.0060","volume":"60","author":"G Ben-Baruch","year":"1996","unstructured":"Ben-Baruch G, Sivan E, Moran O et al. Primary peritoneal serous papillary carcinoma:a study of 25 cases and comparison with stage III ?IV ovarian papillary serous carcinoma. Gynecol Oncol 1996;60:393?6.","journal-title":"Gynecol Oncol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1587::AID-CNCR22>3.0.CO;2-T","volume":"79","author":"LD Kowalski","year":"1997","unstructured":"Kowalski LD, Kanbour AI, Price FV et al. A case-matched comparison of extraovarian versus primary ovarian adenocarci-noma. Cancer 1997;79:1587?94.","journal-title":"Cancer"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/gyno.1998.5090","volume":"71","author":"GH Eltabbakh","year":"1998","unstructured":"Eltabbakh GH, Werness MB, Piver S et al. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol 1998;71:230?9.","journal-title":"Gynecol Oncol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0301-2115(00)00521-2","volume":"97","author":"B Piura","year":"2001","unstructured":"Piura B, Rabinovich A, Yanai-Inbar I. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. Eur J Obstet Gynecol Reprod Biol 2001;97:241?2.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00000478-200202000-00003","volume":"26","author":"SN Agoff","year":"2002","unstructured":"Agoff SN, Mendelin JE, Grieco VS et al. Unexpected gynecologic neoplasm in patients with proven or suspected BRCA-1 or-2 mutations:implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002;26:171?8.","journal-title":"Am J Surg Pathol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","volume":"21","author":"DA Levine","year":"2003","unstructured":"Levine DA, Argenta PA, Yee CJ et al. Fallopian tube andprimary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222?7.","journal-title":"J Clin Oncol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/ng1294-392","volume":"8","author":"J Simard","year":"1994","unstructured":"Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392?8.","journal-title":"Nat Genet"},{"key":"CR15","first-page":"1031","volume":"60","author":"EL Schubert","year":"1997","unstructured":"Schubert EL, Lee MK, Mefford HC et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutatio ns, variable expressi on, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031?40.","journal-title":"Am J Hum Genet"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1999.5623","volume":"76","author":"RP Zweemer","year":"2000","unstructured":"Zweemer RP, van Diest PJ, Verheijen RH et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 mutations. Gynecol Oncol 2000;76:45?50.","journal-title":"Gynecol Oncol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/gyno.2000.5740","volume":"77","author":"PG Rose","year":"2000","unstructured":"Rose PG, Shrigley R, Siesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma:a case report. Gynecol Oncol 2000;77:319?20.","journal-title":"Gynecol Oncol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00000478-200110000-00009","volume":"25","author":"TJ Colgan","year":"2001","unstructured":"Colgan TJ, Murphy J, Cole DE et al. Occult carcinoma in prophylactic oophorectomy specimens:prevalence and associa-tion with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283?9.","journal-title":"Am J Surg Pathol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/gyno.2000.6071","volume":"80","author":"PJ Paley","year":"2001","unstructured":"Paley PJ, Swisher EM, Garcia RL et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophy-lactic oophorectomy:a case for recommending hysterectomy as surgical prophylaxis. Gynecol Oncol 2001;80:176?80.","journal-title":"Gynecol Oncol"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2002.20.5.1260","volume":"20","author":"L Scheuer","year":"2002","unstructured":"Scheuer L, Kauff N, Robson M et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260?8.","journal-title":"J Clin Oncol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1025700807451","volume":"2","author":"JM Piek","year":"2003","unstructured":"Piek JM, Torrenga B, Hermsen B et al. Histopathological characteristics of BRCA1-and BRCA2-associated intraperitoneal cancer:a clinic-based study. Fam Cancer 2003;2:73?8.","journal-title":"Fam Cancer"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0002-9378(59)90287-X","volume":"77","author":"M. Swerdlow","year":"1959","unstructured":"Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary:case report. Am J Obstet Gynecol 1959;77:197?200.","journal-title":"Am J Obstet Gynecol"},{"key":"CR23","first-page":"213","volume":"18","author":"MA Rosenbloom","year":"1961","unstructured":"Rosenbloom MA, Foster RB. Probable pelvic mesothelioma: report of a case and review of the literature. Obstet Gynecol 1961;18:213?22.","journal-title":"Obstet Gynecol"},{"key":"CR24","first-page":"238","volume":"40","author":"B Czernobilsky","year":"1972","unstructured":"Czernobilsky B, Lancet M. Broad ligament adenocarcinoma of Mullerian origin. Obstet Gynecol 1972;40:238?42.","journal-title":"Obstet Gynecol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0002-9378(77)90475-6","volume":"127","author":"M Kannerstein","year":"1977","unstructured":"Kannerstein M, Churg J, McCaughey WTE et al. Papillary tumors of the peritoneum in women:mesothelioma or papillary carcinoma. Am J Obstet Gynecol 1977;127:306?14.","journal-title":"Am J Obstet Gynecol"},{"key":"CR26","first-page":"89","volume":"75","author":"G-L Fromm","year":"1990","unstructured":"Fromm G-L, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89?95.","journal-title":"Obstet Gynecol"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0046-8177(90)90081-F","volume":"21","author":"LD Truong","year":"1990","unstructured":"Truong LD, Maccato ML, Awalt H et al. Serous surface carcinoma of the peritoneum:a clinicopathologic study of 22 cases. Hum Pathol 1990;21:99?110.","journal-title":"Hum Pathol"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00004347-198203000-00003","volume":"1","author":"S Gooneratne","year":"1982","unstructured":"Gooneratne S, Sassone M, Blaustein A et al. Serous surface papillary carcinoma of the ovary:a clinicopathologic study of 16 cases. Int J Gynecol Pathol 1982;1:258?69.","journal-title":"Int J Gynecol Pathol"},{"key":"CR29","first-page":"931","volume":"68","author":"H Hochster","year":"1984","unstructured":"Hochster H, Wernz JC, Muggia FM. Intra-abdominal carcino-matosis with histologically normal ovaries. Cancer Treat Rep 1984;68:931?2.","journal-title":"Cancer Treat Rep"},{"key":"CR30","first-page":"403","volume":"20","author":"PF White","year":"1985","unstructured":"White PF, Merino MJ, Barwick KW. Serous surface papillary carcinoma:a clinical, pathologic, ultrastructural, and immuno-histochemical study of 11 cases. Pathol Annual 1985;20:403?18.","journal-title":"Pathol Annual"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00000478-198811000-00003","volume":"12","author":"SE Mills","year":"1988","unstructured":"Mills SE, Andersen WA, Fechner RE et al. Serous surface papillary carcinoma:a clinicopathologic study of 10 cases and comparison with stage III ?IV ovarian serous carcinoma. Am J Surg Pathol 1988;12:827?34.","journal-title":"Am J Surg Pathol"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/gyno.1993.1223","volume":"50","author":"JD Bloss","year":"1993","unstructured":"Bloss JD, Liao S-Y, Buller RE et al. Extraovarian peritoneal serous papillary carcinoma:a case-control retrospective compar-ison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347?51.","journal-title":"Gynecol Oncol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0090-8258(03)00068-4","volume":"89","author":"JD Bloss","year":"2003","unstructured":"Bloss JD, Brady MF, Liao SY et al. Extraovarian peritoneal serous papillary carcinoma:a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma ?a Gynecologic Oncology Group study. Gynecol Oncol 2003;89:148?54.","journal-title":"Gynecol Oncol"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jama.1960.63030100009018","volume":"174","author":"ML. Bassis","year":"1960","unstructured":"Bassis ML. An embryologically derived classi cation of ovarian tumors. JAMA 1960;174:1316?9.","journal-title":"JAMA"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/00000658-196205000-00011","volume":"155","author":"LA Gray","year":"1962","unstructured":"Gray LA, Barnes ML. Carcinoma of the ovary:a report of 106 cases:1. A further effort at pathological differentiation. Ann Surg 1962;155:722?32.","journal-title":"Ann Surg"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00006254-197203000-00001","volume":"27","author":"SC. Lauchlan","year":"1972","unstructured":"Lauchlan SC. The secondary mullerian system. Obstet Gynecol Surv 1972;27:133?46.","journal-title":"Obstet Gynecol Surv"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0002-9378(74)90370-6","volume":"120","author":"TH Parmley","year":"1974","unstructured":"Parmley TH, Woodruff JD. The ovarian mesothelioma. Am J Obstet Gynecol 1974;120:234?41.","journal-title":"Am J Obstet Gynecol"},{"key":"CR38","first-page":"117","volume":"144","author":"JD. Woodruff","year":"1979","unstructured":"Woodruff JD. The pathogenesis of ovarian neoplasia. Johns Hopkins Med J 1979;144:117?20.","journal-title":"Johns Hopkins Med J"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0306-9877(86)90007-1","volume":"21","author":"HT Lynch","year":"1986","unstructured":"Lynch HT, Bewtra C, Lynch JF. Familial peritoneal ovarian carcinomatosis:a new clinical entity?Med Hypotheses 1986;21:171?7.","journal-title":"Med Hypotheses"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2559.2001.01042.x","volume":"38","author":"KM Feeley","year":"2001","unstructured":"Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87?95.","journal-title":"Histopathology"},{"key":"CR41","first-page":"255","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg N, Wong AS, Choi KC et al. Ovarian surface epithelium:biology, endocrinology, and pathology. Endocr Rev 2001;22:255?88.","journal-title":"Endocr Rev"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0046-8177(77)80067-1","volume":"8","author":"M Kannerstein","year":"1977","unstructured":"Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol 1977;8:83?94.","journal-title":"Hum Pathol"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0090-8258(90)90283-Q","volume":"40","author":"MM Altaras","year":"1991","unstructured":"Altaras MM, Aviram R, Cohen I et al. Primary peritoneal papillary serous adenocarcinoma:clinical and management aspects. Gynecol Oncol 1991;40:230?6.","journal-title":"Gynecol Oncol"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/path.1711490208","volume":"149","author":"PB Silocks","year":"1986","unstructured":"Silocks PB, Herbert A, Wright DH. Evaluation of PAS-diatase and carcinoembryonic antigen staining in the differential diagno-sis of malignant mesothelioma and papillary serous carcinoma of the ovary. J Pathol 1986;149:133?41.","journal-title":"J Pathol"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00004347-198909000-00001","volume":"8","author":"MR Wick","year":"1989","unstructured":"Wick MR, Mills SE, Dehner LP et al. Serous papillary carcino-mas arising from the peritoneum and ovaries. A clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol 1989;8:179?88.","journal-title":"Int J Gynecol Pathol"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00000478-198908000-00004","volume":"13","author":"DJ Bollinger","year":"1989","unstructured":"Bollinger DJ, Wick MR, Dehner LP et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histo-chemical and immunohistochemical comparison. Am J Surg Pathol 1989;13:659?70.","journal-title":"Am J Surg Pathol"},{"key":"CR47","first-page":"931","volume":"135","author":"D Jordan","year":"1989","unstructured":"Jordan D, Jagirdar J, Kaneko M. Blood group antige ns, Lewisx and Lewisy in the diagnostic discrimination of malig-nant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931?7.","journal-title":"Am J Pathol"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0046-8177(90)90050-F","volume":"21","author":"N Khoury","year":"1990","unstructured":"Khoury N, Raju U, Crissman JD et al. A comparative immuno-histochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. Hum Pathol 1990;21:811?9.","journal-title":"Hum Pathol"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF02718376","volume":"251","author":"G Gitsch","year":"1992","unstructured":"Gitsch G, Tabery U, Feigl W et al. The differential diagnosis of primary peritoneal papillary tumors. Arch Gynecol Obstet 1992;251:139?44.","journal-title":"Arch Gynecol Obstet"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/1097-0142(19950801)76:3<429::AID-CNCR2820760313>3.0.CO;2-8","volume":"76","author":"J Zhou","year":"1995","unstructured":"Zhou J, Iwasa Y, Konishi I et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohis-tochemical study. Cancer 1995;76:429?36.","journal-title":"Cancer"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2559.1996.d01-562.x","volume":"30","author":"AC Bateman","year":"1997","unstructured":"Bateman AC, Al-Talib RK, Newman T et al. Immunohisto-chemical phenotype of malignant mesothelioma:predictive value of CA125 and HBME-1 expression. Histopathology 1997;30:49?56.","journal-title":"Histopathology"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/00000478-199810000-00005","volume":"22","author":"NG. Ordonez","year":"1998","unstructured":"Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203?14.","journal-title":"Am J Surg Pathol"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00004347-199510000-00005","volume":"14","author":"D Rothacker","year":"1995","unstructured":"Rothacker D, Mobius G. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany:a thirty-year autopsy study. Int J Gynecol Pathol 1995;14:310?8.","journal-title":"Int J Gynecol Pathol"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0090-8258(88)80010-6","volume":"31","author":"SB Lele","year":"1988","unstructured":"Lele SB, Piver MS, Matharu J et al. Peritoneal papillary carcinoma. Gynecol Oncol 1988;31:315?20.","journal-title":"Gynecol Oncol"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0029-7844(97)00650-9","volume":"91","author":"GH Eltabbakh","year":"1998","unstructured":"Eltabbakh GH, Piver MS, Natarajan N et al. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998;91:254?9.","journal-title":"Obstet Gynecol"},{"key":"CR56","first-page":"171","volume":"18","author":"P Taus","year":"1997","unstructured":"Taus P, Petru E, Gucer F et al. Primary serous papillary carcinoma of the peritoneum:a report of 18 patients. Eur J Gynaecol Oncol 1997;18:171?2.","journal-title":"Eur J Gynaecol Oncol"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/1097-0142(19860915)58:6<1371::AID-CNCR2820580632>3.0.CO;2-L","volume":"58","author":"TK Chen K","year":"1986","unstructured":"Chen K TK, Flam MS. Peritoneal papillary serous carcinoma with long-term survival. Cancer 1986;58:1371?3.","journal-title":"Cancer"},{"key":"CR58","first-page":"656","volume":"54","author":"JE Clark","year":"1979","unstructured":"Clark JE, Wood H, Jaffurs WJ et al. Endometrioid-type cystad-enocarcinoma arising in the mesosalpinx. Obstet Gynecol 1979;54:656?8.","journal-title":"Obstet Gynecol"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2559.1988.tb01972.x","volume":"12","author":"R Banerjee","year":"1988","unstructured":"Banerjee R, Gough FP. Cystic mucinous tumors of the mesentery and retroperitoneum:report of three cases. Histopathology 1988;12:527?32.","journal-title":"Histopathology"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0090-8258(91)90320-5","volume":"41","author":"KR Lee","year":"1991","unstructured":"Lee KR, Verma U, Belinson H. Primary clear cell carcinoma of the peritoneum. Gynecol Oncol 1991;41:259?62.","journal-title":"Gynecol Oncol"},{"key":"CR61","first-page":"844","volume":"79","author":"HL Hampton","year":"1992","unstructured":"Hampton HL, Hufman HT, Meeks GR. Extraovarian Brenner tumors. Obstet Gynecol 1992;79:844?6.","journal-title":"Obstet Gynecol"},{"key":"CR62","first-page":"1044","volume":"119","author":"JL Mira","year":"1995","unstructured":"Mira JL, Fenoglio-Preiser CM, Husseinzadah N. Malignant mixed Mullerian tumor of extraovarian secondary Mullerian system:report of two cases and review of the literature. Arch Pathol Lab Med 1995;119:1044?9.","journal-title":"Arch Pathol Lab Med"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/1097-0142(20010301)91:5<1052::AID-CNCR1097>3.0.CO;2-A","volume":"91","author":"DH Shen","year":"2001","unstructured":"Shen DH, Khoo US, Xue WC et al. Primary peritoneal malignant mixed Mullerian tumors. A clinicopathologic, immunohistochem-ical, and genetic study. Cancer 2001;91:1052?60.","journal-title":"Cancer"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00004347-198805000-00004","volume":"7","author":"M Aslani","year":"1988","unstructured":"Aslani M, Ahn GH, Scully RE. Serous papillary cystadenoma of borderline malignancy of broad ligament. A report of 25 cases. Int J Gynecol Pathol 1988;7:131?8.","journal-title":"Int J Gynecol Pathol"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00000478-199003000-00004","volume":"14","author":"DA Bell","year":"1990","unstructured":"Bell DA, Scully RE. Serous borderline tumors of the peritoneum. Am J Surg Pathol 1990;14:230?9.","journal-title":"Am J Surg Pathol"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00000478-199205000-00005","volume":"16","author":"CV Biscotti","year":"1992","unstructured":"Biscotti CV, Hart WR. Peritoneal serous micropapillomatosis of low malignant potential (serous borderline tumors of the perito-neum):a clinicopathologic study of 17 cases. Am J Surg Pathol 1992;16:467?75.","journal-title":"Am J Surg Pathol"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/1097-0142(19900115)65:2<292::AID-CNCR2820650218>3.0.CO;2-W","volume":"65","author":"D Daya","year":"1990","unstructured":"Daya D, McCaughey WT. Well-differentiated papillary mesothe-lioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer 1990;65:292?6.","journal-title":"Cancer"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/00000478-199807000-00007","volume":"22","author":"MM Weir","year":"1998","unstructured":"Weir MM, Bell DA, Young RH. Grade 1 peritoneal serous carcinoma:a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors. Am J Surg Pathol 1998;22:849?62.","journal-title":"Am J Surg Pathol"},{"key":"CR69","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO;2-5","volume":"58","author":"DG Bostwick","year":"1986","unstructured":"Bostwick DG, Tazelaar HD, Ballon SC et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986;58:2052?65.","journal-title":"Cancer"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/1097-0142(19881115)62:10<2212::AID-CNCR2820621024>3.0.CO;2-W","volume":"62","author":"DA Bell","year":"1988","unstructured":"Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prog-nosis. Cancer 1988;62:2212?22.","journal-title":"Cancer"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00000478-199206000-00005","volume":"16","author":"GH Segal","year":"1992","unstructured":"Segal GH, Hart WR. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophy-tic surface tumor to peritoneal ?implants?. Am J Surg Pathol 1992;16:577?83.","journal-title":"Am J Surg Pathol"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/1097-0142(19920701)70:1<152::AID-CNCR2820700125>3.0.CO;2-6","volume":"70","author":"M deNictolis","year":"1992","unstructured":"deNictolis M, Montironi R, Tommasoni S et al. Serous borderline tumors of the ovary. A clinicopathologic, immuno-histochemic al, and quantitative study of 44 cases. Cancer 1992;70:152?60.","journal-title":"Cancer"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00000478-199611000-00004","volume":"20","author":"JD Seidman","year":"1996","unstructured":"Seidman JD, Kurman RJ. Subclassi cation of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20:1331?45.","journal-title":"Am J Surg Pathol"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1096::AID-CNCR13>3.0.CO;2-1","volume":"82","author":"DM Gershenson","year":"1998","unstructured":"Gershenson DM, Silva EG, Levy L et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998;82:1096?103.","journal-title":"Cancer"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D","volume":"83","author":"DM Gershenson","year":"1998","unstructured":"Gershenson DM, Silva EG, Tortolero-Luna G et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 1998;83:2157?63.","journal-title":"Cancer"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00000478-199904000-00004","volume":"23","author":"JH Eichorn","year":"1999","unstructured":"Eichorn JH, Bell DA, Young RH et al. Ovarian serous borderline tumors with micropapillary and cribiform patterns:a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999;23:397?409.","journal-title":"Am J Surg Pathol"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/hp.2000.8048","volume":"31","author":"JD Seidman","year":"2000","unstructured":"Seidman JD, Kurman RJ. Ovarian serous borderline tumors:a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31:539?57.","journal-title":"Hum Pathol"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00000478-200104000-00001","volume":"25","author":"KA Bell","year":"2001","unstructured":"Bell KA, Smith-Sehdev AE, Kurman RJ. Re ned diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline)and micropapillary serous carcinomas. Am J Surg Pathol 2001;25:419?32.","journal-title":"Am J Surg Pathol"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00004347-200110000-00003","volume":"20","author":"KR Lee","year":"2001","unstructured":"Lee KR, Castrillon DH, Nucci MR. Pathologic ndings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma. Int J Gynecol Pathol 2001;20:329?34.","journal-title":"Int J Gynecol Pathol"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0090-8258(03)00331-7","volume":"90","author":"F Lackman","year":"2003","unstructured":"Lackman F, Carey MS, Kirk ME et al. Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecol Oncol 2003;90:407?12.","journal-title":"Gynecol Oncol"},{"key":"CR81","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1241::AID-CNCR7>3.0.CO;2-N","volume":"80","author":"G Saretzki","year":"1997","unstructured":"Saretzki G, Hoffmann U, Rohlke P et al. Identi cation of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 1997;80:1241?9.","journal-title":"Cancer"},{"key":"CR82","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jnci\/90.13.995","volume":"90","author":"WH Gotlieb","year":"1998","unstructured":"Gotlieb WH, Friedman E, Bar-Sade RB et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998;90:995?1000.","journal-title":"J Natl Cancer Inst"},{"key":"CR83","first-page":"34","volume":"93","author":"KH Lu","year":"1999","unstructured":"Lu KH, Cramer DW, Muto MG et al. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 1999;93:34?7.","journal-title":"Obstet Gynecol"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0046-8177(00)80014-3","volume":"31","author":"BA Werness","year":"2000","unstructured":"Werness BA, Ramus SJ, Whittemore AS et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000;31:1420?4.","journal-title":"Hum Pathol"},{"key":"CR85","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","volume":"97","author":"I Cass","year":"2003","unstructured":"Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187?95.","journal-title":"Cancer"},{"key":"CR86","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DEC et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700?10.","journal-title":"Am J Hum Genet"},{"key":"CR87","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/j.1600-0412.1999.781013.x","volume":"78","author":"A Dorum","year":"1999","unstructured":"Dorum A, Heimdal K, Lovslett K et al. Prospectively detected cancer in familial breast\/ovarian cancer screening. Acta Obstet Gynecol Scand 1999;78:906?11.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0046-8177(90)90201-F","volume":"21","author":"DA Bell","year":"1990","unstructured":"Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion:a report of 21 cases. Hum Pathol 1990;21:397?403.","journal-title":"Hum Pathol"},{"key":"CR89","first-page":"663","volume":"10","author":"EG Silva","year":"1997","unstructured":"Silva EG, Tornos CS, Malpica A et al. Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma. Mod Pathol 1997;10:663?7.","journal-title":"Mod Pathol"},{"key":"CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004347-199801000-00001","volume":"17","author":"EG Silva","year":"1998","unstructured":"Silva EG, Tornos C, Zhuang Z et al. Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol 1998;17:1?6.","journal-title":"Int J Gynecol Pathol"},{"key":"CR91","first-page":"3","volume":"99","author":"MA Crispens","year":"2002","unstructured":"Crispens MA, Bordurka D, Deavers M et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99:3?10.","journal-title":"Obstet Gynecol"},{"key":"CR92","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<278::AID-CNCR14>3.0.CO;2-T","volume":"78","author":"AW Kennedy","year":"1996","unstructured":"Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carci-noma. Cancer 1996;78:278?86.","journal-title":"Cancer"},{"key":"CR93","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1072-7515(02)01250-4","volume":"195","author":"S Camette","year":"2002","unstructured":"Camette S, Morice P, Atallah D et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor:an analysis of a series of 42 lympha-denectomies. J Am Coll Surg 2002;195:332?8.","journal-title":"J Am Coll Surg"},{"key":"CR94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004347-200301000-00008","volume":"22","author":"CB Gilks","year":"2003","unstructured":"Gilks CB, Alkushi A, Yue JJ et al. Advanced-stage serous borderline tumors of the ovary:a clinicopathological study of 49 cases. Int J Gynecol Pathol 2003;22:29?36.","journal-title":"Int J Gynecol Pathol"},{"key":"CR95","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0090-8258(92)90099-5","volume":"47","author":"JF Leake","year":"1992","unstructured":"Leake JF, Currie JL, Rosenshein NB et al. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992;47:150?8.","journal-title":"Gynecol Oncol"},{"key":"CR96","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/1097-0142(19930301)71:5<1810::AID-CNCR2820710516>3.0.CO;2-V","volume":"71","author":"J Kaern","year":"1993","unstructured":"Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993;71:1810?20.","journal-title":"Cancer"},{"key":"CR97","first-page":"11","volume":"99","author":"BM Buttin","year":"2002","unstructured":"Buttin BM, Herzog TJ, Powell MA et al. Epithelial ovarian tumors of low malignant potential:the role of microinvasion. Obstet Gynecol 2002;99:11?7.","journal-title":"Obstet Gynecol"},{"key":"CR98","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/gyno.2002.6711","volume":"86","author":"CL Trimble","year":"2002","unstructured":"Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002;86:34?7.","journal-title":"Gynecol Oncol"},{"key":"CR99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0090-8258(92)90267-M","volume":"46","author":"M Shiraki","year":"1992","unstructured":"Shiraki M, Otis CN, Donovan JT et al. Ovarian serous borderline epithelial tumors with multiple retroperitoneal nodal involvement: metastasis or malignant transformation of epithelial glandular inclusions?Gynecol Oncol 1992;46:255?8.","journal-title":"Gynecol Oncol"},{"key":"CR100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00007611-199304000-00010","volume":"86","author":"TL Goldman","year":"1993","unstructured":"Goldman TL, Chalas E, Chumas L et al. Management of borderline tumors of the ovary. South Med J 1993;86:423?5.","journal-title":"South Med J"},{"key":"CR101","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1072-7515(02)01250-4","volume":"195","author":"S Camatte","year":"2002","unstructured":"Camatte S, Morice P, Atallah D et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor:an analysis of a series of 42 lympha-denectomies. J Am Coll Surg 2002;195:332?8.","journal-title":"J Am Coll Surg"},{"key":"CR102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00004347-199004000-00002","volume":"9","author":"CB Gilks","year":"1990","unstructured":"Gilks CB, Bell DA, Scully RE. Serous psammocarcinoma of the ovary and peritoneum.Int J Gynecol Pathol 1990;9:110?21.","journal-title":"Int J Gynecol Pathol"},{"key":"CR103","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(82)92681-2","volume":"2","author":"JK Tobacman","year":"1982","unstructured":"Tobacman JK, Greene MH, Tucker MA et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-can-cer-prone families. Lancet 1982;2:795?7.","journal-title":"Lancet"},{"key":"CR104","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0090-8258(92)90147-B","volume":"47","author":"GM Kemp","year":"1992","unstructured":"Kemp GM, Hsiu J-G, Andrews MC. Papillary peritoneal carci-nomatosis after prophylactic oophorectomy. Gynecol Oncol 1992;47:395?7.","journal-title":"Gynecol Oncol"},{"key":"CR105","first-page":"558","volume":"80","author":"AM Weber","year":"1992","unstructured":"Weber AM, Hewett WJ, Gajewski WH et al. Serous carcinoma of the peritoneum after oophorectomy. Obstet Gynecol 1992;80:558?60.","journal-title":"Obstet Gynecol"},{"key":"CR106","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J","volume":"71","author":"MS Piver","year":"1993","unstructured":"Piver MS, Jishi MF, Tsukada Y et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer:a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751?5.","journal-title":"Cancer"},{"key":"CR107","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2002.20.6.1570","volume":"20","author":"A Liede","year":"2002","unstructured":"Liede A, Karlan BY, Baldwin RL et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 2002;20:1570?7.","journal-title":"J Clin Oncol"},{"key":"CR108","unstructured":"Chen KT, Schooley JL, Flam MS. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 1985;66(Suppl):93S ?4S."},{"key":"CR109","first-page":"166","volume":"9","author":"J Kupryjanczyk","year":"1996","unstructured":"Kupryjanczyk J, Thor AD, Beauchamp R et al. Ovari an, peritone al, and endometrial serous carcinoma:clonal origin of multifocal disease. Mod Pathol 1996;9:166?73.","journal-title":"Mod Pathol"},{"key":"CR110","first-page":"490","volume":"55","author":"MG Muto","year":"1995","unstructured":"Muto MG, Welch WR, Mok SC et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995;55:490?2.","journal-title":"Cancer Res"},{"key":"CR111","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/sj.onc.1201901","volume":"16","author":"CA Bandera","year":"1998","unstructured":"Bandera CA, Muto MG, Welch WR et al. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 1998;16:3455?9.","journal-title":"Oncogene"},{"key":"CR112","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jnci\/90.11.841","volume":"90","author":"JO Schorge","year":"1998","unstructured":"Schorge JO, Muto MG, Bandera CA et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998;90:841?5.","journal-title":"J Natl Cancer Inst"},{"key":"CR113","first-page":"89","volume":"68","author":"JO Schorge","year":"1998","unstructured":"Schorge JO, Muto MG, Welch WR et al. Androgen receptor genetic analysis of the X-chromosome inactivation pattern in patients with papillary serous carcinoma of the peritoneum. Gynecol Oncol 1998;68:89.","journal-title":"Gynecol Oncol"},{"key":"CR114","first-page":"1361","volume":"60","author":"JO Schorge","year":"2000","unstructured":"Schorge JO, Muto MG, Lee SJ et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000;60:1361?4.","journal-title":"Cancer Res"},{"key":"CR115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00004347-199704000-00012","volume":"16","author":"TM Moll","year":"1997","unstructured":"Moll TM, Valea F, Chimas J. Role of p53 alteration in primary peritoneal carcinoma. Int J Gynecol Pathol 1997;16:156?62.","journal-title":"Int J Gynecol Pathol"},{"key":"CR116","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0002-9378(99)70663-0","volume":"180","author":"BY Karlan","year":"1999","unstructured":"Karlan BY, Baldwin RL, Lopez-Luevanos E et al. Peritoneal serous papillary carcino ma, a phenotypic variant of familial ovarian cancer:implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180:917?28.","journal-title":"Am J Obstet Gynecol"},{"key":"CR117","first-page":"2328","volume":"58","author":"KH Lu","year":"1998","unstructured":"Lu KH, Bell DA, Welch WR et al. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998;58:2328?30.","journal-title":"Cancer Res"},{"key":"CR118","first-page":"7264","volume":"61","author":"BH Ortiz","year":"2001","unstructured":"Ortiz BH, Ailawade M, Colitti C et al. Second primary or recurrence?Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 2001;61:7264?7.","journal-title":"Cancer Res"},{"key":"CR119","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/gyno.1999.5568","volume":"75","author":"G Hornreich","year":"1999","unstructured":"Hornreich G, Beller U, Lavie O et al. Is uterine serous carcinoma a BRCA1-related disease?Case report and review of the literature. Gynecol Oncol 1999;75:300?4.","journal-title":"Gynecol Oncol"},{"key":"CR120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/gyno.2000.6003","volume":"79","author":"R Goshen","year":"2000","unstructured":"Goshen R, Chu W, Elit L et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?Gynecol Oncol 2000;79:477?81.","journal-title":"Gynecol Oncol"},{"key":"CR121","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2003.11.009","volume":"92","author":"O Lavie","year":"2004","unstructured":"Lavie O, Hornreich G, Ben-Arie A et al. BRCA germline mutations in Jewish women with uterine serous papillary carci-noma. Gynecol Oncol 2004;92:521?4.","journal-title":"Gynecol Oncol"},{"key":"CR122","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/gyno.1998.5046","volume":"70","author":"EJ Kaplan","year":"1998","unstructured":"Kaplan EJ, Caputo TA, Shen PU et al. Familial papillary serous carcinoma of the cervix, peritoneum, and ovary:a report of the rst case. Gynecol Oncol 1998;70:289?94.","journal-title":"Gynecol Oncol"},{"key":"CR123","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/gyno.2000.6082","volume":"80","author":"DA Levine","year":"2001","unstructured":"Levine DA, Lin O, Barakat RR et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001;80:395?8.","journal-title":"Gynecol Oncol"},{"key":"CR124","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identi ed in a risk evaluation program. J Natl Cancer Inst 2002;94:1365?72.","journal-title":"J Natl Cancer Inst"},{"key":"CR125","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Breast Cancer Linkage Consortium.","year":"1999","unstructured":"Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310?6.","journal-title":"J Natl Cancer Inst"},{"key":"CR126","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton DF, The Breast Cancer Linkage Consor-tium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358?65.","journal-title":"J Natl Cancer Inst"},{"key":"CR127","first-page":"28","volume":"96","author":"O Lavie","year":"2000","unstructured":"Lavie O, Hornreich G, Ben-Arie A et al. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 2000;96:28?32.","journal-title":"Obstet Gynecol"},{"key":"CR128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185?7.","journal-title":"Nat Genet"},{"key":"CR129","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616?22.","journal-title":"N Engl J Med"},{"key":"CR130","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609?15.","journal-title":"N Engl J Med"},{"key":"CR131","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/jnci\/88.24.1810","volume":"88","author":"H Salazar","year":"1996","unstructured":"Salazar H, Godwin AK, Daly MB et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810?20.","journal-title":"J Natl Cancer Inst"},{"key":"CR132","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/jnci\/91.7.626","volume":"91","author":"JF Stratton","year":"1999","unstructured":"Stratton JF, Buckley CH, Lowe D et al. Comparison of prophylactic oophorectomy specimens from carriers and noncar-riers of a BRCA1 or BRCA2 gene mutation. J Natl Cancer Inst 1999;91:626?8.","journal-title":"J Natl Cancer Inst"},{"key":"CR133","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJM199705153362022","volume":"336","author":"D Schrag","year":"1997","unstructured":"Schrag D, Kuntz KM, Garber JE et al. Decision analysis ?effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465?71.","journal-title":"N Engl J Med"},{"key":"CR134","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","volume":"343","author":"D Ford","year":"1994","unstructured":"Ford D, Easton DF, Bishop DT et al. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692?5.","journal-title":"Lancet"},{"key":"CR135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajmg.1320560305","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT et al. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995;56:265?71.","journal-title":"Am J Hum Genet"},{"key":"CR136","first-page":"957","volume":"57","author":"S Narod","year":"1995","unstructured":"Narod S, Ford D, Devilee P et al. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995;57:957?8.","journal-title":"Am J Hum Genet"},{"key":"CR137","first-page":"254","volume":"56","author":"SA Narod","year":"1995","unstructured":"Narod SA, Ford D, Devilee P et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995;56:254?64.","journal-title":"Am J Hum Genet"},{"key":"CR138","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","volume":"61","author":"DF Easton","year":"1997","unstructured":"Easton DF, Steele L, Fields P et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120?8.","journal-title":"Am J Hum Genet"},{"key":"CR139","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676?89.","journal-title":"Am J Hum Genet"},{"key":"CR140","first-page":"1457","volume":"57","author":"D Ford","year":"1995","unstructured":"Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457?62.","journal-title":"Am J Hum Genet"},{"key":"CR141","first-page":"496","volume":"60","author":"AS Whittemore","year":"1997","unstructured":"Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer:results from three population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496?504.","journal-title":"Am J Hum Genet"},{"key":"CR142","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ng1095-198","volume":"11","author":"JP Struewing","year":"1995","unstructured":"Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198?200.","journal-title":"Nat Genet"},{"key":"CR143","first-page":"188","volume":"14","author":"C Oddoux","year":"1996","unstructured":"Oddoux C, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %Nat Genet 1996;14:188?90.","journal-title":"The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %Nat Genet"},{"key":"CR144","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.2000.5848","volume":"78","author":"DH Tobias","year":"2000","unstructured":"Tobias DH, Eng C, McCurdy LD et al. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol 2000;78:148?51.","journal-title":"Gynecol Oncol"},{"key":"CR145","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0090-8258(03)00152-5","volume":"89","author":"G Hirsh-Yechezkel","year":"2003","unstructured":"Hirsh-Yechezkel G, Chetrit A, Lubin F et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol 2003;89:494?8.","journal-title":"Gynecol Oncol"},{"key":"CR146","first-page":"1059","volume":"60","author":"E Levy-Lahad","year":"1997","unstructured":"Levy-Lahad E, Catane R, Eisenberg S et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel:freqeuncy and di. erential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059?67.","journal-title":"Am J Hum Genet"},{"key":"CR147","first-page":"505","volume":"60","author":"D Abeliovich","year":"1997","unstructured":"Abeliovich D, Kaduri L, Lerer I et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 % of ovarian cancer and 30 % of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505?14.","journal-title":"Am J Hum Genet"},{"key":"CR148","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/gyno.1997.4844","volume":"67","author":"U Beller","year":"1997","unstructured":"Beller U, Halle D, Catane R et al. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patien ts, regardless of family history. Gynecol Oncol 1997;67:123?6.","journal-title":"Gynecol Oncol"},{"key":"CR149","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nm1196-1179","volume":"2","author":"P Tonin","year":"1996","unstructured":"Tonin P, Weber B, Of t K et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families [see comments ]. Nat Med 1996;2:1179?83.","journal-title":"Nat Med"},{"key":"CR150","first-page":"307","volume":"19","author":"G Llort","year":"2002","unstructured":"Llort G, Munoz CY, Tuser MP et al. Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. HumMutat 2002;19:307.","journal-title":"HumMutat"},{"key":"CR151","first-page":"1199","volume":"334","author":"C Sher","year":"1996","unstructured":"Sher C, Sharabani-Gargir L, Shohat M. Breast cancer and BRCA1 mutations. N Engl J Med 1996;334:1199.","journal-title":"N Engl J Med"},{"key":"CR152","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1054\/bjoc.2000.1332","volume":"83","author":"H Yazici","year":"2000","unstructured":"Yazici H, Bitisik O, Akisik E et al. BRCA1 and BRCA2 mutations in Turkish breast\/ovarian families and young breast cancerpatients. Br J Cancer 2000;83:737?42.","journal-title":"Br J Cancer"},{"key":"CR153","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/95.14.1072","volume":"95","author":"JL Rutter","year":"2003","unstructured":"Rutter JL, Wacholder S, Chetrit A et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations:an Israeli population-based case-control study. J Natl Cancer Inst 2003;95:1072?8.","journal-title":"J Natl Cancer Inst"},{"key":"CR154","first-page":"596","volume":"92","author":"CA Bandera","year":"1998","unstructured":"Bandera CA, Muto MG, Schorge JO et al. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998;92:596?600.","journal-title":"Obstet Gynecol"},{"key":"CR155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/gyno.2002.6853","volume":"88","author":"J Menczer","year":"2003","unstructured":"Menczer J, Chetrit A, Barda G et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 2003;88:58?61.","journal-title":"Gynecol Oncol"},{"key":"CR156","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","volume":"18","author":"KH Lu","year":"2000","unstructured":"Lu KH, Garber JE, Cramer DW et al. Occult ovarian tumors in women with BRCA1 and BRCA2 mutations undergoing prophy-lactic oophorectomy. J Clin Oncol 2000;18:2728?32.","journal-title":"J Clin Oncol"},{"key":"CR157","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jama.1995.03520310033026","volume":"273","author":"D Shattuck-Eidens","year":"1995","unstructured":"Shattuck-Eidens D, McClure M, Simard J et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene:Implications for presymptomatic testing and screening. JAMA 1995;273:535?41.","journal-title":"JAMA"},{"key":"CR158","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ng1295-428","volume":"11","author":"SA Gayther","year":"1995","unstructured":"Gayther SA, Warren W, Mazoyer S et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype ?phenotype correlation. Nat Genet 1995;11:428?33.","journal-title":"Nat Genet"},{"key":"CR159","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ng0197-103","volume":"15","author":"SA Gayther","year":"1997","unstructured":"Gayther SA, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103?5.","journal-title":"Nat Genet"},{"key":"CR160","first-page":"329","volume":"11","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002;11:329?36.","journal-title":"Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev"},{"key":"CR161","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","volume":"68","author":"D Thompson","year":"2001","unstructured":"Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in cancer ris ks, by mutation positi on, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410?9.","journal-title":"Am J Hum Genet"},{"key":"CR162","first-page":"42","volume":"58","author":"O Serova","year":"1996","unstructured":"Serova O, Montagna M, Torchard D et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 1996;58:42?51.","journal-title":"Am J Hum Genet"},{"key":"CR163","first-page":"1166","volume":"58","author":"DB Berman","year":"1996","unstructured":"Berman DB, Wagner-Costalas J, Schultz DC et al. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families:a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 1996;58:1166?76.","journal-title":"Am J Hum Genet"},{"key":"CR164","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0090-8258(91)90051-6","volume":"43","author":"TH Bourne","year":"1991","unstructured":"Bourne TH, Whitehead MI, Campbell S et al. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991;43:92?7.","journal-title":"Gynecol Oncol"},{"key":"CR165","first-page":"14","volume":"80","author":"N Einhorn","year":"1992","unstructured":"Einhorn N, Sjovall K, Knapp RC et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14?8.","journal-title":"Obstet Gynecol"},{"key":"CR166","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/jnci\/85.21.1748","volume":"85","author":"RP Woolas","year":"1993","unstructured":"Woolas RP, Xu FJ, Jacobs IJ et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Insts 1993;85:1748?51.","journal-title":"J Natl Cancer Insts"},{"key":"CR167","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/bmj.306.6884.1030","volume":"306","author":"I Jacobs","year":"1993","unstructured":"Jacobs I, Davies AP, Bridges J et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measure-ment and ultrasonography. BMJ 1993;306:1030?4.","journal-title":"BMJ"},{"key":"CR168","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/gyno.1994.1065","volume":"52","author":"TH Bourne","year":"1994","unstructured":"Bourne TH, Campbell S, Reynolds K et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994;52:379?85.","journal-title":"Gynecol Oncol"},{"key":"CR169","doi-asserted-by":"crossref","unstructured":"Karlan BY, Platt LD. Ovarian cancer screening:the role of ultrasound in early detection. Cancer 1995;76(10 Suppl): 2011 ?5.","DOI":"10.1002\/1097-0142(19951115)76:10+<2011::AID-CNCR2820761318>3.0.CO;2-L"},{"key":"CR170","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.313.7069.1355","volume":"313","author":"IJ Jacobs","year":"1996","unstructured":"Jacobs IJ, Skates S, Davies AP et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration:a prospective cohort study. BMJ 1996;313:1355?8.","journal-title":"BMJ"},{"key":"CR171","first-page":"265","volume":"25","author":"HT Lynch","year":"1998","unstructured":"Lynch HT, Casey MJ, Lynch J et al. Genetics and ovarian carcinoma. Semin Oncol 1998;25:265?81.","journal-title":"Semin Oncol"},{"key":"CR172","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","volume":"353","author":"IJ Jacobs","year":"1999","unstructured":"Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer:a pilot randomised controlled trial. Lancet 1999;353:1207?10.","journal-title":"Lancet"},{"key":"CR173","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1006\/gyno.2000.5816","volume":"77","author":"JR van Nagell Jr.","year":"2000","unstructured":"van Nagell Jr. JR, DePriest PD, Reedy MB et al. The ef cacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350?6.","journal-title":"Gynecol Oncol"},{"key":"CR174","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1054\/bjoc.2000.1174","volume":"82","author":"T Meyer","year":"2000","unstructured":"Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535?8.","journal-title":"Br J Cancer"},{"key":"CR175","volume-title":"Principles and Practice of Gynecologic Oncology","author":"HT Lynch","year":"2000","unstructured":"Lynch HT, Lynch JF, Casey MJ et al. Genetics of gynecological cancer. In Hoskins WJ, Perez CA, Young RC (eds):Principles and Practice of Gynecologic Oncology. Philadelphia, Pennsylva-nia:Lippincott-Raven Publishers, 2000;29 ?53."},{"key":"CR176","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","volume":"336","author":"JP Struewing","year":"1997","unstructured":"Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with speci c mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments ]. N Engl J Med 1997;336:1401?8.","journal-title":"N Engl J Med"},{"key":"CR177","first-page":"3776","volume":"8","author":"JM Satagopan","year":"2002","unstructured":"Satagopan JM, Boyd J, Kauff ND et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2. Clin Cancer Res 2002;8:3776?81.","journal-title":"Clin Cancer Res"},{"key":"CR178","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 muta-tions detected in case series unselected for family history:a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117?30 [Erratum in Am J Hum Genet] 2003;73:709.","journal-title":"Am J Hum Genet"},{"key":"CR179","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643?6.","journal-title":"Science"},{"key":"CR180","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.1998.16.3.979","volume":"16","author":"VR Grann","year":"1998","unstructured":"Grann VR, Panageas KS, Whang W et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998;16:979?85.","journal-title":"J Clin Oncol"},{"key":"CR181","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jama.283.5.617","volume":"283","author":"D Schrag","year":"2000","unstructured":"Schrag D, Kuntz KM, Garber JE et al. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000;283:617?24.","journal-title":"JAMA"},{"key":"CR182","first-page":"13","volume":"6","author":"VR Grann","year":"2000","unstructured":"Grann VR, Jacobson JS, Whang W et al. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1\/2-positive women:a decision analysis. Cancer J Sci Am 2000;6:13?20.","journal-title":"Cancer J Sci Am"},{"key":"CR183","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2002.10.101","volume":"20","author":"VR Grann","year":"2002","unstructured":"Grann VR, Jacobson JS, Thomason D et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1 \/2 mutations:an updated decision analysis. J Clin Oncol 2002;20:2520?9.","journal-title":"J Clin Oncol"},{"key":"CR184","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/jco.2002.08.035","volume":"20","author":"MS van Roosmalen","year":"2002","unstructured":"van Roosmalen MS, Verhoef L CG, Stalmeier PFM et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers:a more prominent role for oophorectomy. J Clin Oncol 2002;20:2092?100.","journal-title":"J Clin Oncol"},{"key":"CR185","first-page":"33","volume":"17","author":"JP Struewing","year":"1995","unstructured":"Struewing JP, Watson P, Easton DF et al. Prophylactic oopho-rectomy in inherited breast\/ovarian cancer families. J Natl Cancer Inst Monogr 1995;17:33?5.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"CR186","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR, Levin AM, Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475?9.","journal-title":"J Natl Cancer Inst"},{"key":"CR187","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(00)04642-0","volume":"357","author":"SA Narod","year":"2001","unstructured":"Narod SA, Sun P, Ghadirian P et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations:a case-control study. Lancet 2001;357:1467?70.","journal-title":"Lancet"},{"key":"CR188","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/oxfordjournals.aje.a116098","volume":"134","author":"KL Irwin","year":"1991","unstructured":"Irwin KL, Weiss NS, Lee NC et al. Tubal sterilizati on, hyster-ecto my, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 1991;134:362?9.","journal-title":"Am J Epidemiol"},{"key":"CR189","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.1993.03510230051034","volume":"270","author":"SE Hankinson","year":"1993","unstructured":"Hankinson SE, Hunter DJ, Colditz GA et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270:2813?8.","journal-title":"JAMA"},{"key":"CR190","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<948::AID-IJC6>3.0.CO;2-Y","volume":"71","author":"A Green","year":"1997","unstructured":"Green A, PUrdie D, Bain C et al. Tubal sterilisati on, hysterec-tomy and decreased risk of ovarian cancer. Survey of Women 's Health Study Group. Int J Cancer 1997;71:948?51.","journal-title":"Int J Cancer"},{"key":"CR191","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/oxfordjournals.aje.a009112","volume":"145","author":"HL Miracle-McMahill","year":"1997","unstructured":"Miracle-McMahill HL, Calle EE, Kosinski AS et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol 1997;145:349?57.","journal-title":"Am J Epidemiol"},{"key":"CR192","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/gyno.2000.6071","volume":"80","author":"TJ Colgan","year":"2001","unstructured":"Colgan TJ, Murphy J, Cole DE et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophy-lactic oophorectomy. Gynecol Oncol 2001;80:176?80.","journal-title":"Gynecol Oncol"},{"key":"CR193","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451?6.","journal-title":"J Pathol"},{"key":"CR194","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00000478-200110000-00009","volume":"25","author":"L Scheuer","year":"2001","unstructured":"Scheuer L, Kauff N, Robson M et al. Occult carcinoma in prophylactic oophorectomy specimens:prevalence and associa-tion with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283?9.","journal-title":"Am J Surg Pathol"},{"key":"CR195","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2002.20.5.1260","volume":"20","author":"PJ Paley","year":"2002","unstructured":"Paley PJ, Swisher EM, Garcia RL et al. Outcome and preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260?8.","journal-title":"J Clin Oncol"},{"key":"CR196","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/gyno.2002.6779","volume":"87","author":"L Leeper","year":"2002","unstructured":"Leeper L, Garcia R, Swisher E et al. Pathologic ndings in prophylactic oophorectomy specimens in high-risk women. Gyne-col Oncol 2002;87:52?6.","journal-title":"Gyne-col Oncol"},{"key":"CR197","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/clon.2000.9113","volume":"12","author":"A Hartley","year":"2000","unstructured":"Hartley A, Rollason T, Spooner D. Clear cell carcinoma of the mbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin Oncol (R Coll Radiol)2000;12:58?9.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"CR198","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1155\/1999\/278269","volume":"15","author":"A Borg","year":"1999","unstructured":"Borg A, Dorum A, Heimdal K et al. 167delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations. Dis Markers 1999;15:79?84.","journal-title":"Dis Markers"},{"key":"CR199","unstructured":"Lynch HT, Casey MJ, Lynch JF et al. Hereditary cancer in women. In Greggi S, Mancuso S, Pecorelli S (eds):Familial and Hereditary Cancer in Women. Milan:Poletto Editore, 1999;24 ?46."},{"key":"CR200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001703-200102000-00004","volume":"13","author":"HT Lynch","year":"2001","unstructured":"Lynch HT, Casey MJ. Current status of prophylactic surgery for hereditary breast and gynecologic cancers. Curr Opin Obstet Gynecol 2001;13:25?30.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"CR201","first-page":"111","volume":"1","author":"MJ Casey","year":"1995","unstructured":"Casey MJ, Bewtra C, Garcia-Padial J et al. Laparoscopic exami-nation and assisted bilateral salpingo-oophorectomy hysterectomy for prophylactic removal of the ovaries and uterus in women at genetic risk for ovarian cancer. J Gynecol Tech 1995;1:111?4.","journal-title":"J Gynecol Tech"},{"key":"CR202","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","volume":"293","author":"DC Smith","year":"1975","unstructured":"Smith DC, Prentice R, Thompson DJ. Assocation of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164?7.","journal-title":"N Engl J Med"},{"key":"CR203","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","volume":"293","author":"HK Ziel","year":"1975","unstructured":"Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167?70.","journal-title":"N Engl J Med"},{"key":"CR204","first-page":"301","volume":"18","author":"RD. Gambrell Jr","year":"1977","unstructured":"Gambrell Jr RD. Estrogens, progestogens and endometrial cancer. J Reprod Med 1977;18:301?16.","journal-title":"J Reprod Med"},{"key":"CR205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0002-9378(79)90289-8","volume":"133","author":"CB Hammond","year":"1979","unstructured":"Hammond CB, Jelovsek FR, Lee KL et al. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 1979;133:537?47.","journal-title":"Am J Obstet Gynecol"},{"key":"CR206","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1532-5415.1979.tb01673.x","volume":"27","author":"RD Gambrell Jr","year":"1979","unstructured":"Gambrell Jr. RD, Massey FM, Castaneda TA et al. Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens. J Am Geriatr Soc 1979;27:389?94.","journal-title":"J Am Geriatr Soc"},{"key":"CR207","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0378-5122(86)90022-8","volume":"8","author":"RD. Gambrell Jr","year":"1986","unstructured":"Gambrell Jr RD. Prevention of endometrial cancer with progest-ogens. Maturitas 1986;8:159?68.","journal-title":"Maturitas"},{"key":"CR208","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.298.6667.147","volume":"298","author":"I Persson","year":"1989","unstructured":"Persson I, Adami H-O, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens:results of a prospective study. BMJ 1989;298:147?51.","journal-title":"BMJ"},{"key":"CR209","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF01831376","volume":"5","author":"C Schairer","year":"1994","unstructured":"Schairer C, Byrne C, Keyl PM et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5:491?500.","journal-title":"Cancer Causes Control"},{"key":"CR210","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJM199506153322401","volume":"332","author":"GA Colditz","year":"1995","unstructured":"Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589?93.","journal-title":"N Engl J Med"},{"key":"CR211","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0002-9378(96)70201-6","volume":"174","author":"GD Giraud","year":"1996","unstructured":"Giraud GD, Morton MJ, Wilson RA et al. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women. Am J Obstet Gynecol 1996;174:1708?17.","journal-title":"Am J Obstet Gynecol"},{"key":"CR212","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199608153350701","volume":"335","author":"F Grodstein","year":"1996","unstructured":"Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453?61.","journal-title":"N Engl J Med"},{"key":"CR213","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"S Hulley","year":"1998","unstructured":"Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605?13.","journal-title":"JAMA"},{"key":"CR214","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0002-9378(98)70553-8","volume":"178","author":"JH Pickar","year":"1998","unstructured":"Pickar JH, Thorneycroft I, Whitehead M. Effects of hormone replacement therapy on the endometrium and lipid parameters:a review of randomized clinical trials. Am J Obstet Gynecol 1998;178:1087?99.","journal-title":"Am J Obstet Gynecol"},{"key":"CR215","unstructured":"Bush TL. Preserving cardiovascular bene ts of hormone replace-ment therapy. J Reprod Med 2000;45(3 Suppl):259 ?73."},{"key":"CR216","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2001.tb04014.x","volume":"949","author":"DM Herrington","year":"2001","unstructured":"Herrington DM, Klein KP. Cardiovascular trials of estrogen replacement therapy. Ann NY Acad Sci 2001;949:153?62.","journal-title":"Ann NY Acad Sci"},{"key":"CR217","doi-asserted-by":"crossref","first-page":"36E","DOI":"10.1016\/S0002-9149(02)02411-6","volume":"89","author":"RD. Langer","year":"2002","unstructured":"Langer RD. Hormone replacement and the prevention of cardio-vascular disease. Am J Cardiol 2002;89(12 Suppl):36E?46E.","journal-title":"Am J Cardiol"},{"key":"CR218","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00045415-200201000-00010","volume":"10","author":"GM Rosano","year":"2002","unstructured":"Rosano GM, Fini M. Postmenopausal women and cardiovascular risk:impact of hormone replacement therapy and atherosclerosis. Cardiol Rev 2002;10:51?60.","journal-title":"Cardiol Rev"},{"key":"CR219","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11883-002-0077-4","volume":"4","author":"JE Ho","year":"2002","unstructured":"Ho JE, Mosca L. Postmenopausal hormone replacement therapy and atherosclerosis. Curr Atheroscler Rep 2002;4:387?95.","journal-title":"Curr Atheroscler Rep"},{"key":"CR220","doi-asserted-by":"crossref","unstructured":"Shulman LP. Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in post-menopausal women. Am J Cardiol 2002;89(12 Suppl):47E ?55E.","DOI":"10.1016\/S0002-9149(02)02413-X"},{"key":"CR221","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371?88.","journal-title":"J Natl Cancer Inst"},{"key":"CR222","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"M-C King","year":"2001","unstructured":"King M-C, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2:National Surgical Adjuvant Breast and Bowel Project (NSABP-P1)breast cancer prevention trial. JAMA 2001;286:2251?6.","journal-title":"JAMA"},{"key":"CR223","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296?300.","journal-title":"Lancet"},{"key":"CR224","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0959-8049(97)89007-7","volume":"33","author":"OT Jo \u00b4hannsson","year":"1997","unstructured":"Jo \u00b4hannsson OT, Idvall I, Anderson C et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362?71.","journal-title":"Eur J Cancer"},{"key":"CR225","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W","volume":"83","author":"N Loman","year":"1998","unstructured":"Loman N, Johannsson O, Bendahl P-O et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310?9.","journal-title":"Cancer"},{"key":"CR226","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0959-8049(98)00248-2","volume":"34","author":"P Osin","year":"1998","unstructured":"Osin P, Gusterson BA, Philip E et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998;34:1683?6.","journal-title":"Eur J Cancer"},{"key":"CR227","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.1998.16.5.1642","volume":"16","author":"M Robson","year":"1998","unstructured":"Robson M, Gilewski T, Haas B et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642?9.","journal-title":"J Clin Oncol"},{"key":"CR228","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01811244","volume":"12","author":"G Bertelli","year":"1988","unstructured":"Bertelli G, Pronzato P, Amortoso D et al. Adjuvant tamoxifen in primary breast cancer:in. uence on plasma lipids and antithrom-bin III levels. Breast Cancer Res 1988;12:307?10.","journal-title":"Breast Cancer Res"},{"key":"CR229","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.1988.248","volume":"58","author":"PF Bruning","year":"1988","unstructured":"Bruning PF, Bonfrer JM, Hart AA et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58:497?9.","journal-title":"Br J Cancer"},{"key":"CR230","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/jcem-70-4-1132","volume":"70","author":"JD Bagdade","year":"1990","unstructured":"Bagdade JD, Wolter J, Subbaiah PV et al. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132?5.","journal-title":"J Clin Endocrinol Metab"},{"key":"CR231","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jnci\/85.17.1398","volume":"85","author":"LE Rutqvist","year":"1993","unstructured":"Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbid-ity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1398.","journal-title":"J Natl Cancer Inst"},{"key":"CR232","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","volume":"86","author":"RR Love","year":"1994","unstructured":"Love RR, Wiebe DA, Feyzi JM et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534?9.","journal-title":"J Natl Cancer Inst"},{"key":"CR233","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/oxfordjournals.annonc.a010715","volume":"7","author":"J Chang","year":"1996","unstructured":"Chang J, Powles TJ, Ashley SE et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann Oncol 1996;7:671?5.","journal-title":"Ann Oncol"},{"key":"CR234","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/jnci\/89.11.776","volume":"89","author":"JP Costantino","year":"1997","unstructured":"Costantino JP, Kuller LH, Ives DG et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776?82.","journal-title":"J Natl Cancer Inst"},{"key":"CR235","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.1997.15.2.840","volume":"15","author":"WJ Graddishar","year":"1997","unstructured":"Graddishar WJ, Jordan VC. Clinical potential of new antiestro-gens. J Clin Oncol 1997;15:840?52.","journal-title":"J Clin Oncol"},{"key":"CR236","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3181\/00379727-217-44204","volume":"217","author":"HU Bryant","year":"1998","unstructured":"Bryant HU, Dere WH. Selective estrogen receptor modulators:an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 1998;217:45?52.","journal-title":"Proc Soc Exp Biol Med"},{"key":"CR237","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/00912709922008416","volume":"39","author":"D Goldfrank","year":"1999","unstructured":"Goldfrank D, Haytoglu T, Frishman WH et al. Raloxife ne, a new selective estrogen receptor modulator. J Clin Pharmacol 1999;39:767?74.","journal-title":"J Clin Pharmacol"},{"key":"CR238","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1365-2125.1998.00733.x","volume":"45","author":"CR Meier","year":"1998","unstructured":"Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;45:608?12.","journal-title":"Br J Clin Pharmacol"},{"key":"CR239","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","volume":"91","author":"MH Gail","year":"1999","unstructured":"Gail MH, Costantino JP, Bryant J et al. Weighing the risks and bene ts of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829?46.","journal-title":"J Natl Cancer Inst"},{"key":"CR240","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2003.10.111","volume":"21","author":"C Duggan","year":"2003","unstructured":"Duggan C, Marriott K, Edwards R et al. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588?93.","journal-title":"J Clin Oncol"},{"key":"CR241","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<325::AID-IJC7>3.0.CO;2-X","volume":"76","author":"H Mignotte","year":"1998","unstructured":"Mignotte H, Lasset C, Bonadona V et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998;76:325?30.","journal-title":"Int J Cancer"},{"key":"CR242","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/91.19.1654","volume":"91","author":"L Bernstein","year":"1999","unstructured":"Bernstein L, Deapen D, Cerhan J et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654?62.","journal-title":"J Natl Cancer Inst"},{"key":"CR243","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1006126411210","volume":"54","author":"C Peters-Engl","year":"1999","unstructured":"Peters-Engl C, Frank W, Danmayr E et al. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 1999;54:255?60.","journal-title":"Breast Cancer Res Treat"},{"key":"CR244","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/oxfordjournals.annonc.a010406","volume":"11","author":"Y Matsuyama","year":"2000","unstructured":"Matsuyama Y, Tominaga T, Nomura Y et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 2000;11:1537?43.","journal-title":"Ann Oncol"},{"key":"CR245","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","volume":"356","author":"L Bergman","year":"2000","unstructured":"Bergman L, Beelen ML, Gallee MP et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Compre-hensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial Cancer Risk Following Tamoxifen. Lancet 2000;356:881?7.","journal-title":"Lancet"},{"key":"CR246","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0301-2115(00)00376-6","volume":"95","author":"M Ursic-Vrscaj","year":"2001","unstructured":"Ursic-Vrscaj M, Kovacic J, Bebar S et al. Endometrial and other primary cancers after tamoxifen treatment of breast cancer ? results of retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 2001;95:105?10.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"CR247","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ijc.10454","volume":"100","author":"E Pukkla","year":"2002","unstructured":"Pukkla E, Kyyronen P, Sankila R et al. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer:a population-based case-control study. Int J Cancer 2002;100:337?41.","journal-title":"Int J Cancer"},{"key":"CR248","first-page":"202","volume":"20","author":"P Morice","year":"1999","unstructured":"Morice P, Mercier S, Spatz A et al. Laparoscopic prophylactic oophorectomy in women with inherited risk of ovarian cancer. Eur J Gynaecol Oncol 1999;20:202?4.","journal-title":"Eur J Gynaecol Oncol"},{"key":"CR249","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1096-9098(199909)72:1<9::AID-JSO3>3.0.CO;2-7","volume":"72","author":"GH Eltabbakh","year":"1999","unstructured":"Eltabbakh GH, Piver MS, Hempling RE et al. Laparoscopic management of women with a family history of ovarian cancer. J Surg Oncol 1999;72:9?13.","journal-title":"J Surg Oncol"},{"key":"CR250","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/gyn.1992.8.81","volume":"8","author":"J Garcia-Padial","year":"1992","unstructured":"Garcia-Padial J, Sotolongo J, Casey MJ et al. Laparoscopy-assisted vaginal hysterectomy:report of seventy-ve consecutive cases. J Gynecol Surg 1992;8:81?5.","journal-title":"J Gynecol Surg"},{"key":"CR251","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/gyn.1994.10.7","volume":"10","author":"MJ Casey","year":"1994","unstructured":"Casey MJ, Garcia-Padial J, Johnson C et al. A critical analysis of laparoscopic assisted vaginal hysterectomies compared with vaginal hysterectomies unassisted by laparoscopy and transab-dominal hysterectomies. J Gynecol Surg 1994;10:7?14.","journal-title":"J Gynecol Surg"},{"key":"CR252","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1006\/gyno.2002.6638","volume":"85","author":"TJ Colgan","year":"2002","unstructured":"Colgan TJ, Boerner SL, Murphy J et al. Peritoneal lavage cytology:an assessment of its value during prophylactic oopho-rectomy. Gynecol Oncol 2002;85:397?403.","journal-title":"Gynecol Oncol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-004-9554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-004-9554-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-004-9554-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:45:53Z","timestamp":1559238353000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-004-9554-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":252,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2004]]}},"alternative-id":["5379554"],"URL":"https:\/\/doi.org\/10.1007\/s10689-004-9554-y","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}